These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 31882997)

  • 1. Development of prime-boost-type next-generation mucosal vaccines.
    Fujimoto K; Uematsu S
    Int Immunol; 2020 Sep; 32(9):597-603. PubMed ID: 31882997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigen-Specific Mucosal Immunity Regulates Development of Intestinal Bacteria-Mediated Diseases.
    Fujimoto K; Kawaguchi Y; Shimohigoshi M; Gotoh Y; Nakano Y; Usui Y; Hayashi T; Kimura Y; Uematsu M; Yamamoto T; Akeda Y; Rhee JH; Yuki Y; Ishii KJ; Crowe SE; Ernst PB; Kiyono H; Uematsu S
    Gastroenterology; 2019 Dec; 157(6):1530-1543.e4. PubMed ID: 31445037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine therapy for dysbiosis-related diseases.
    Fujimoto K; Uematsu S
    World J Gastroenterol; 2020 Jun; 26(21):2758-2767. PubMed ID: 32550752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New horizon of mucosal immunity and vaccines.
    Takahashi I; Nochi T; Yuki Y; Kiyono H
    Curr Opin Immunol; 2009 Jun; 21(3):352-8. PubMed ID: 19493665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined prime-boost immunization with systemic and mucosal pneumococcal vaccines based on Pneumococcal surface protein A to enhance protection against lethal pneumococcal infections.
    Zhang Y; Guo X; Guo M; Chen X; Li B; Yu J; Gu T; Kong W; Wu Y
    Immunol Res; 2019 Oct; 67(4-5):398-407. PubMed ID: 31773490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of mucosal immunity through systemic immunization: Phantom or reality?
    Su F; Patel GB; Hu S; Chen W
    Hum Vaccin Immunother; 2016 Apr; 12(4):1070-9. PubMed ID: 26752023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranasal vaccination of recombinant H5N1 HA1 proteins fused with foldon and Fc induces strong mucosal immune responses with neutralizing activity: Implication for developing novel mucosal influenza vaccines.
    Yu F; Li Y; Guo Y; Wang L; Yang J; Zhao G; Zhou Y; Du L; Jiang S
    Hum Vaccin Immunother; 2015; 11(12):2831-8. PubMed ID: 26260706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimized Mucosal Modified Vaccinia Virus Ankara Prime/Soluble gp120 Boost HIV Vaccination Regimen Induces Antibody Responses Similar to Those of an Intramuscular Regimen.
    Jones DI; Pollara JJ; Johnson-Weaver BT; LaBranche CC; Montefiori DC; Pickup DJ; Permar SR; Abraham SN; Maddaloni M; Pascual DW; Staats HF
    J Virol; 2019 Jul; 93(14):. PubMed ID: 31068425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prime-boost-type PspA3 + 2 mucosal vaccine protects cynomolgus macaques from intratracheal challenge with pneumococci.
    Yokota C; Fujimoto K; Yamakawa N; Kono M; Miyaoka D; Shimohigoshi M; Uematsu M; Watanabe M; Kamei Y; Sugimoto A; Kawasaki N; Yabuno T; Okamura T; Kuroda E; Hamaguchi S; Sato S; Hotomi M; Akeda Y; Ishii KJ; Yasutomi Y; Sunami K; Uematsu S
    Inflamm Regen; 2023 Nov; 43(1):55. PubMed ID: 37964391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal vaccines: Strategies and challenges.
    Li M; Wang Y; Sun Y; Cui H; Zhu SJ; Qiu HJ
    Immunol Lett; 2020 Jan; 217():116-125. PubMed ID: 31669546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous approach using systemic, mucosal and transcutaneous routes of immunization for development of protective HIV-1 vaccines.
    Belyakov IM; Ahlers JD
    Curr Med Chem; 2011; 18(26):3953-62. PubMed ID: 21824096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA.
    McCluskie MJ; Weeratna RD; Payette PJ; Davis HL
    FEMS Immunol Med Microbiol; 2002 Feb; 32(3):179-85. PubMed ID: 11934561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New perspectives in vaccine development: mucosal immunity to infections.
    McGhee JR; Kiyono H
    Infect Agents Dis; 1993 Apr; 2(2):55-73. PubMed ID: 8162356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospects for human mucosal vaccines.
    Mestecky J; McGhee JR
    Adv Exp Med Biol; 1992; 327():13-23. PubMed ID: 1295333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal immunization with heat-inactivated Streptococcus pneumoniae protects mice against systemic pneumococcal infection.
    Hvalbye BK; Aaberge IS; Løvik M; Haneberg B
    Infect Immun; 1999 Sep; 67(9):4320-5. PubMed ID: 10456869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outer membrane vesicle-based intranasal vaccines.
    Van der Ley P; Schijns VE
    Curr Opin Immunol; 2023 Oct; 84():102376. PubMed ID: 37598549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel mucosal vaccine targeting Peyer's patch M cells induces protective antigen-specific IgA responses.
    Shima H; Watanabe T; Fukuda S; Fukuoka S; Ohara O; Ohno H
    Int Immunol; 2014 Nov; 26(11):619-25. PubMed ID: 24908678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attachment of class B CpG ODN onto DOTAP/DC-chol liposome in nasal vaccine formulations augments antigen-specific immune responses in mice.
    Tada R; Muto S; Iwata T; Hidaka A; Kiyono H; Kunisawa J; Aramaki Y
    BMC Res Notes; 2017 Jan; 10(1):68. PubMed ID: 28126014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Per-oral immunization with antigen-conjugated nanoparticles followed by sub-cutaneous boosting immunization induces long-lasting mucosal and systemic antibody responses in mice.
    Howe SE; Konjufca VH
    PLoS One; 2015; 10(2):e0118067. PubMed ID: 25710518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inducing Mucosal IgA: A Challenge for Vaccine Adjuvants and Delivery Systems.
    Boyaka PN
    J Immunol; 2017 Jul; 199(1):9-16. PubMed ID: 28630108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.